Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.


GREY:SRNE - Post by User

Sorrento Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by zeropointenergyon Oct 06, 2021 7:09am
330 Views
Post# 33972344

ONE DRUG PILL WIPES OUT COVID 19!

ONE DRUG PILL WIPES OUT COVID 19!

India's Ivermectin Blackout - Part V: The Secret Revealed ...

Sep 27, 2021 · By September 12, 2021, Livemint reported that 34 districts were declared COVID-free or had no active cases. Only 14 new cases were recorded in

INDIA DECLARES POPULATED STATE COVID FREE AFTER IVERMECTIN ...

Oct 03, 2021 · INDIA GOVT. DECLARES MOST POPULATED STATE OFFICIALLY COVID FREE AFTER WIDESPREAD USE OF IVERMECTIN. VIDEO: Well well.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities